Nilutamide

CAS 63612-50-0 2 current recordsSmall Molecule

Who holds supplier records for Nilutamide? 2 organisations hold a current record for Nilutamide: an active US FDA Type II Drug Master File or a CEP. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (2).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Nilutamide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/nilutamide

Reading the evidence

  • 2 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    2 of the 2 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • No company-level GMP certificate matched

    No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.

Current records (2)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Nilutamide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Nilutamide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (1)

Certificates of Suitability on the EDQM register for Nilutamide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. HyderabadIN
CEP 2017-225 - Rev 01
Nilutamide
Feb 2024—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Overview

Nilutamide is a nonsteroidal antiandrogen used in the treatment of prostate cancer. It works by inhibiting the action of androgens, which are male hormones necessary for the growth and proliferation of prostate cancer cells.

Chemical identity

IUPAC name
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Canonical SMILES
CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
InChIKey
XWXYUMMDTVBTOU-UHFFFAOYSA-N
Synonyms
Nilandron API, nilandron, nsc-758683, ru 23908, ru-23908

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Androgen Receptor Inhibitor
Mechanism of action
Androgen Receptor Antagonists

Therapeutic areas

OncologyEndocrinology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Nilutamide?

2 organisations hold an active US FDA Type II Drug Master File or a CEP for Nilutamide: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India) and KEKULE PHARMA LTD (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Nilutamide Drug Master Files are active?

BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 28262) and KEKULE PHARMA LTD (DMF 25465). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Nilutamide have a European Certificate of Suitability?

Yes. 1 organisation holds a valid CEP for Nilutamide on the EDQM register, including BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. Hyderabad (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Nilutamide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Nilutamide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.